LOXO ONCOLOGY, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.loxooncology.com
Clinical Trials
23
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT06588478
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸City of Hope National Medical Center, Irvine, California, United States
🇺🇸Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto, California, United States
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple SclerosisMultiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT06104683
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Clinical Trial Network, Houston, Texas, United States
🇺🇸Swedish Medical Center-501 E Hampden Ave, Seattle, Washington, United States
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05324124
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaLeukemia, B-cellLeukemia, LymphocyticSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 662
- Registration Number
- NCT05254743
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05176314
- Locations
- 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next